BioCentury
ARTICLE | Management Tracks

CureVac CEO Hoerr takes leave of absence; German biotech rejects reports of U.S. approach for COVID-19 vaccine

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

March 16, 2020 6:24 PM UTC
Updated on Mar 25, 2020 at 7:33 PM UTC

Ingmar Hoerr didn’t last long as CureVac’s newly re-appointed CEO. The German biotech said Monday that the company’s founder and chairman would take a temporary leave of absence for medical reasons unrelated to COVID-19.

The move is the latest in what has been a turbulent two weeks for CureVac AG...

BCIQ Company Profiles

BioNTech SE

CureVac N.V.